Study
Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001004027 | Other |
Study Description
Key Points• Multiple mechanisms of acquired CD19 mutations and splicing contribute to CD19 loss and relapse to blinatumomab.• Identification of CD19 ex2part levels represents a new biomarker predictive of resistance or likely failure of blinatumomab
Study Datasets 5 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001005729 |
WGS files for Mullighan BiTE WGS paper titled "Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia"
|
Illumina HiSeq 2000 | 56 |
| EGAD00001005730 |
WXS files for Mullighan BiTE WXS paper titled "Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia"
|
Illumina HiSeq 2000 | 60 |
| EGAD00001005731 |
RNAseq files for Mullighan BiTE RNASEQ1 paper titled "Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia"
|
Illumina HiSeq 2000 | 41 |
| EGAD00001005732 |
lowinput RNASEQ files for Mullighan BiTE RNASEQ2 paper titled "Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia"
|
Illumina HiSeq 2000 | 10 |
| EGAD00001005733 |
single cell RNASEQ files for Mullighan BiTE RNASEQ3 paper titled "Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab in relapsed/refractory acute lymphoblastic leukemia"
|
Illumina HiSeq 2000 | 10 |
Who archives the data?
